Diabetes
Refine Search
Pharmaceutical
Gliptins, oral medicines that can reduce the blood sugar levels in type 2 diabetes, are all the rage in India. With the country hosting over 67 million diabetes patients, type 2 diabetes mellitus is also gaining epidemic proportions, reports The Pharma Letter’s India correspondent. 16 July 2015
Pharmaceutical
Last week, Europe’s Innovative Medicines Initiative (IMI) launched its fifth Call for proposals under the IMI 2 program. 13 July 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk has announced positive headline results from SUSTAIN1, the first Phase IIIa trial for semaglutide, a new GLP-1 analogue administered once-weekly. 11 July 2015
Pharmaceutical
Eli Lilly and Sumitomo Dainippon Pharma have signed a sales collaboration agreement for diabetes drug Trulicity (dulaglutide). 9 July 2015
Pharmaceutical
India’s Lee Pharma has filed a compulsory license (CL) application for the patent covering Anglo-Swedish pharma major AstraZeneca’s diabetes management drug saxagliptin, marketed under the trade name Onglyza, according to local media reports. 9 July 2015
Pharmaceutical
China-based Wuzhou Zhongheng Group has paid $52 million for a 10% stake in Oramed Pharma and China rights to its two diabetes treatments. 6 July 2015
Pharmaceutical
The Japanese subsidiary of US pharma major Eli Lilly has received manufacturing and marketing approval in Japan for Torurishiti subcutaneous injection. 6 July 2015
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for insulin glargine [rDNA origin] injection from French drug major Sanofi. 3 July 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk says it will cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany. 1 July 2015
Biotechnology
Clinical-stage biotech company Vitae Pharmaceuticals has announced that its drug BI187004/VTP-34072 failed in the metformin arm of an ongoing Phase II trial in overweight type 2 diabetes. 30 June 2015
Pharmaceutical
The global insulin market is expected to reach a value of $47.54 billion by 2020, according to a new study by Grand View Research. 30 June 2015
Biotechnology
Privately held Dutch biotech firm Amarna Therapeutics has entered into a cooperation with the Austrian Center for Biomarker Research in Medicine (CBmed), for the development of immunotherapies. 29 June 2015
Pharmaceutical
Novo Nordisk today announced that the European Medicines agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir (insulin detemir) in children with diabetes as young as one year old. 26 June 2015
Pharmaceutical
Anglo-Swedish drug major AstraZeneca has undertaken collaborations with the University of Michigan and the French National Institute of Health and Medical Research (Inserm), both on kidney disease. 17 June 2015
Pharmaceutical
Germany’s Bayer has reached agreement to sell its Diabetes Care business to Japan-based Panasonic Healthcare, a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corp. 10 June 2015
Pharmaceutical
US pharma giant Merck & Co has announced the primary results of a placebo-controlled study of the cardiovascular safety of its DPP-4 inhibitor, Januvia (sitagliptin). 10 June 2015
Pharmaceutical
Sanofi announced positive results for its Toujeo (insulin glargine) in a Phase III study extension in Japanese people with uncontrolled diabetes. 8 June 2015
Pharmaceutical
Danish insulin giant Novo Nordisk has presented results at the American Diabetes Association meeting showing its Victoza (liraglutide) gives improvement in blood glucose control in adults with type 2 diabetes fasting during Ramadan. 8 June 2015
Pharmaceutical
A partnership has been concluded between Anglo-Swedish pharma major AstraZeneca and the two Algerian companies, Salhi and Hasnaoui, for the production of drugs in Algeria. 8 June 2015
Pharmaceutical
Novo Nordisk said today that Xultophy (insulin degludec/liraglutide; IDegLira), the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba) and GLP-1 receptor agonist (liraglutide, Victoza) in one pen, has been launched in the UK. 8 June 2015
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze